FindTrial
Sign In

Clinical study of remimazolam in combination with esketamine for patients undergoing cesarean section

Clinical study of remimazolam in combination with esketamine for patients undergoing cesarean section

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113870
Enrollment
Unknown
Registered
2025-12-04
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean section

Interventions

RK Group:Remimazolam and esketamine
K Group:Esketamine
R Group:Remimazolam

Sponsors

Xing’an League People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: The infants were ASA I-II grade, full-term singletons, delivered by cesarean section, and had consented to participate in the study by signing an informed consent form.

Exclusion criteria

Exclusion criteria: Allergy to the investigational drug, severe pregnancy complications (severe preeclampsia), mental disorders, and other serious systemic diseases.

Design outcomes

Secondary

MeasureTime frame
Blood pressure ;PONV;—

Primary

MeasureTime frame
Visual analogue scale for pain, VAS;Edinburgh Postnatal Depression Scal, EPDS;Heart rate ;—

Countries

China

Contacts

Public ContactCao Xue

Xing’an League People’s Hospital

675225601@qq.com+86 158 4981 0683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026